Cargando…
Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial
BACKGROUND: Standard treatment for drug-susceptible tuberculosis (DS-TB) includes a multidrug regimen requiring at least 6 months of treatment, and this lengthy treatment easily leads to poor adherence. There is an urgent need to simplify and shorten treatment regimens to reduce interruption and adv...
Autores principales: | Feng, Zhen, Miao, Yan, Peng, Ying, Sun, Feng, Zhang, Yilin, Li, Rong, Ge, Shijia, Chen, Xinchang, Song, Lingyun, Li, Yang, Wang, Xiaomeng, Zhang, Wenhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165810/ https://www.ncbi.nlm.nih.gov/pubmed/37158831 http://dx.doi.org/10.1186/s12879-023-08264-2 |
Ejemplares similares
-
Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial
por: Weng, Taoping, et al.
Publicado: (2021) -
Ability of the MeltPro MTB/PZA Assay to Detect Susceptibility to Pyrazinamide in Rifampin-Resistant Tuberculosis Patients
por: Li, Rong, et al.
Publicado: (2023) -
Potential Economic Viability of Two Proposed Rifapentine-Based Regimens for Treatment of Latent Tuberculosis Infection
por: Holland, David P., et al.
Publicado: (2011) -
Study protocol for safety and efficacy of all-oral shortened regimens for multidrug-resistant tuberculosis: a multicenter randomized withdrawal trial and a single-arm trial [SEAL-MDR]
por: Fu, Liang, et al.
Publicado: (2023) -
Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection
por: Borisov, Andrey S., et al.
Publicado: (2018)